Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI315 in HER2-expressing advanced solid tumors
NCT04162327Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Nov 2019
- Primary completion
- Jan 2022
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of IBI315 in solid tumor (advanced stage) (2 arms), sponsored by Innovent Biologics. Primary endpoints: Area under the plasma concentration-time curve up to 9 months, Maximum plasma concentration up to 9 months and 2 more. Started Nov 2019; status: completed.
02
Drugs
IBI315
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04162327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162327.